Strictly Pharmaceuticals ApS
APSIn liquidationAdvertising protectionCVR 42088838Maglehøj 15, 3520 FarumInvesteringsselskaber· NACE 643030Est. 2021 · 5 years old— employees
Loading company…
Overview
Strictly Pharmaceuticals ApS is a Danish APS based in Farum, operating in the Investeringsselskaber sector. Incorporated in 2021.
Gross profit 2022
—
EBITDA margin
—
Net profit 2022
-0.7K DKK
+98% vs 2021
Key ratios
See full ratios →Solidity ratioEquity ÷ Total assets × 100
100.0 %
Very strongAmong the 10% highest rated companies in the industry
20212022
Liquidity ratioCurrent assets ÷ Short-term debt
0.0×
20212022
Return on assets (ROA)Net profit ÷ Total assets × 100
-11.4 %
Very weakAmong the 20% lowest rated companies in the industry
20212022
EBITDA — year on year
DKK thousandsKey figures
Annual report 2022| Gross profit | — | — |
| EBITDA | -0.7K DKK | +99% |
| Net profit | -0.7K DKK | +98% |
| Total assets | 6K DKK | -10% |
| Equity | 6K DKK | -10% |
| Employees | — | — |
Company information
Legal name
Strictly Pharmaceuticals ApS
CVR number
42088838
Legal form
Anpartsselskab
NACE code
643030 · Investeringsselskaber
Founded
31 January 2021 · 5 years
Share capital
DKK 50,000
Employees
—
VAT registered
No
Audit selected
No
Last report
2022-09-30
Financial year
January – December
Signatory rights
Virksomheden tegnes af en likvidator
Contact
Address
Maglehøj 15, 3520 Farum
Advertising protection
Active — opted out of marketing use
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
Financial development
The figures on this page draw on 2 annual filings covering 2021 to 2022. The bottom line showed a net loss of DKK 681.
At the end of 2022, equity financed 100% of the balance sheet.
Financials
Revenue
DKKEBITDA
DKK thousandsIncome statement
DKK thousands| Item | 2022 | 2021 |
|---|---|---|
| Revenue | — | 0 |
| Staff expenses | -0 | -0 |
| EBITDA | -1 | -49 |
| Depreciation & amort. | -0 | -0 |
| EBIT | -1 | -49 |
| Net financials | 0 | 0 |
| Profit before tax | -1 | -49 |
| Tax | -0 | -6 |
| Net profit | -1 | -43 |
Get a credit rating – not just the numbers
Financial statements show the past. Risika gives you a score and a recommended credit limit, so you know what the numbers mean for your risk.
Balance sheet
DKK thousands| Item | 2022 | 2021 |
|---|---|---|
| Total assets | 6 | 7 |
| Equity | 6 | 7 |
| Long-term debt | 0 | 0 |
| Short-term debt | 0 | 0 |
| Total debt | 0 | 0 |
Financial ratios
5-year trendEBITDA margin
<−999 %
20212022
Equity ratio
100.0 %
Very strongAmong the 10% highest rated companies in the industry
20212022
Return on equity
-11.4 %
Very weakAmong the 20% lowest rated companies in the industry
20212022
Net profit margin
<−999 %
20212022
Asset turnover
0.00×
20212022
Debt / equity
0.00×
20212022
Sector performance
11 of 28 ratios graded28 financial ratios from the latest filing, each graded against companies in the same industry.
Profitability
Return on equity (ROE)Very weak
Among the 20% lowest rated companies in the industry
Net profit as a percentage of equity — the return the owners earned on their invested capital this year.
Return on assets (ROA)Very weak
Among the 20% lowest rated companies in the industry
Net profit as a percentage of total assets — the return generated on the capital employed.
Return on net assets (RONA)Very weak
Among the 20% lowest rated companies in the industry
Profit relative to net assets (total assets minus total debt) — the ability to generate earnings from the net asset base alone.
Basic earning power (BEP)Very weak
Among the 10% lowest rated companies in the industry
EBIT relative to total assets — the company's earning power before the effects of tax and financial leverage.
Gross marginNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
The gross result as a share of revenue — how much of the revenue is left after variable costs to cover the company's fixed costs.
Operating marginNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
EBIT as a share of revenue — the share of revenue remaining as earnings once all operating costs are covered. A key measure of earning power.
Net profit marginNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
The profit for the year as a share of revenue — the company's ability to turn revenue into profit.
Capacity ratioNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Shows how strongly fixed costs weigh on the gross result — a high ratio means fixed costs take only a small bite out of the earnings from basic operations.
Liquidity
Current assets to equityWeak
Among the 30% lowest rated companies in the industry
Current assets relative to equity — an indicator of the balance-sheet structure and of the company's short- and long-term financing. The healthy level is highly industry-dependent.
Fixed assets to long-term capitalVery strong
Among the 10% highest rated companies in the industry
Fixed assets relative to long-term capital (equity plus long-term liabilities). Below 100% means the long-term capital finances more than just the fixed assets — a healthier liquidity position.
Cash conversion ratioVery strong
Among the 20% highest rated companies in the industry
Cash flow relative to profit — the ability to convert reported profits into accessible cash.
Current ratioNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Current assets relative to short-term debt — the ability to settle short-term obligations with current assets alone. Around 150% is considered satisfactory from a credit perspective.
Quick ratioNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Current assets excluding inventory relative to short-term debt — whether the most liquid assets alone can cover the short-term obligations. A value of 1 or above signals a healthy liquidity position.
Cash ratioNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Cash relative to short-term debt — the ability to repay short-term obligations with cash alone.
Debt & solvency
Solidity ratioVery strong
Among the 10% highest rated companies in the industry
Equity as a share of total assets — the ability to absorb losses. Around 40% is considered satisfactory from a credit perspective.
Liabilities to equityVery strong
Among the 10% highest rated companies in the industry
Total liabilities relative to equity — whether the company operates primarily on borrowed capital or on its own.
Debt ratioNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Total debt relative to the balance-sheet total — the share of the assets financed by debt rather than equity.
Debt to equityNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Debt relative to equity — the company's leverage. A higher value means heavier reliance on debt financing.
Income to debtNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Profit relative to debt — the ability to create earnings while operating with debt.
EBITDA to debtNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
EBITDA relative to debt — how much operating earnings are available to service the debt.
Interest coverageNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
The ability to pay the interest on the company's debt out of its earnings.
Interest rate on debtNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Financial expenses relative to total liabilities — the effective interest rate the company pays on its debt.
Interest marginNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
The return on assets minus the interest rate on debt. Positive means the company benefits from operating with debt; negative means the debt makes it worse off.
Efficiency & development
Equity to contributed capitalVery weak
Among the 20% lowest rated companies in the industry
Total equity relative to the capital the owners contributed — how the equity has developed from its starting point.
One-year change in equityWeak
Among the 30% lowest rated companies in the industry
The size of this year's increase or decrease in the company's equity.
Asset turnoverNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Revenue relative to total assets — the ability to generate revenue from the asset base.
Inventory turnoverNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Revenue relative to inventory — how many times a year the inventory is sold and replaced. A low value can indicate weak sales or excess inventory.
One-year change in debtNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
The size of this year's increase or decrease in the company's debt.
Annual reports & filings
People & ownership
Management
Actively employed in the business| Name | Role | Member since |
|---|
Former (2)
KD Management | Management | 2021 – 2021 |
SW Management | Management | 2021 – 2022 |
Board of directors
Non-executive oversightNo data on file.
Shareholders
Active legal owners| Shareholder | Type | Ownership | Votes | Registered |
|---|---|---|---|---|
| Individual | 100% | 100% | 2021 | |
| Company | 100% | 100% | 2021 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
One in three Danish companies experiences fraud
Sound familiar? See how to strengthen your defences and catch suspicious changes in ownership and management in time.
Related companies
Company hierarchy
JCCD 1 ApS
Strictly Pharmaceuticals ApS Board network connections
Board members of Strictly Pharmaceuticals ApS also hold positions in 9 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Søren Wonsild Glud | Management | 5 companies |
| Kirsten Dolsø | Management | 4 companies |
Frequently asked questions
What is the CVR number of Strictly Pharmaceuticals ApS?
Strictly Pharmaceuticals ApS is registered with CVR / Virk under CVR 42088838.
Where is Strictly Pharmaceuticals ApS headquartered?
Strictly Pharmaceuticals ApS's registered address is Maglehøj 15.